Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-6259

Roser, P; Vollenweider, F X; Kawohl, W (2010). Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World Journal of Biological Psychiatry, 11(2 Pt 2):208-219.

[img] PDF - Registered users only
View at publisher


Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. These effects of Delta(9)-THC can be reduced in animal and human models of psychopathology by two exogenous cannabinoids, cannabidiol (CBD) and SR141716. CBD is the second most abundant constituent of Cannabis sativa that has weak partial antagonistic properties at the CB(1) receptor. CBD inhibits the reuptake and hydrolysis of anandamide, the most important endogenous CB(1) receptor agonist, and exhibits neuroprotective antioxidant activity. SR141716 is a potent and selective CB(1) receptor antagonist. Since both CBD and SR141716 can reverse many of the biochemical, physiological and behavioural effects of CB(1) receptor agonists, it has been proposed that both CBD and SR141716 have antipsychotic properties. Various experimental studies in animals, healthy human volunteers, and schizophrenic patients support this notion. Moreover, recent studies suggest that cannabinoids such as CBD and SR141716 have a pharmacological profile similar to that of atypical antipsychotic drugs. In this review, both preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action.


38 citations in Web of Science®
40 citations in Scopus®
Google Scholar™



17 downloads since deposited on 03 Jan 2009
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Clinical and Social Psychiatry Zurich West (former)
04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Psychiatry, Psychotherapy, and Psychosomatics
Dewey Decimal Classification:610 Medicine & health
Deposited On:03 Jan 2009 12:27
Last Modified:05 Apr 2016 12:36
Publisher:Informa Healthcare
Additional Information:This is an electronic version of an article published in World Journal of Biological Psychiatry (Epub ahead of print). The World Journal of Biological Psychiatry is available online at http://www.informaworld.com/smpp/content~db=all?content=10.1080/15622970801908047
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.3109/15622970801908047
PubMed ID:20218784

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page